Analyst Ratings for Pacific Biosciences of California (PACB)
PACB Rating Summary
PACB Price Target Summary
- Highest: $3.00 (Canaccord)
- Lowest: $1.50 (Barclays)
- Average: $2.04
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$2.04 (+45.7%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 43%
Avg. $ Target:
$2.04 (+45.7%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 43%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | Barclays » Updated 5/11/2026 |
Luke Sergott | Downgrade | Underweight (Equalweight) |
1.50 (1.00) |
1.52 (1.40) |
-7.89% | Details |
| 11/11/2024 | UBS » Updated 2/14/2025 |
John Sourbeer | Downgrade | Neutral (Buy) |
1.50 (2.00) |
2.30 (1.40) |
-39.13% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
